Document Type
Symposia Article
Abstract
This Article examines the emergence of two modern pharmaceutical companies: Myriad and Moderna. After providing a brief background on each company, this Article contrasts them across the following areas: the technologies they have brought to market; their location; their start-up stages and the role that venture capital played in catalyzing their evolution from start-ups to large corporate structures; their relationships with other entities in the private sector, in academia and in the public sector; and their intellectual property and licensing strategies.
DOI
10.37419/JPL.V11.I1.3
First Page
67
Last Page
94
Recommended Citation
Ana Santos Rutschman,
From Myriad to Moderna: The Modern (Bio)Pharmaceutical Company,
11
Tex. A&M J. Prop. L.
67
(2025).
Available at:
https://doi.org/10.37419/JPL.V11.I1.3